journal

Oncology (Williston Park, NY)

journal
https://read.qxmd.com/read/32293695/hpv-and-the-immune-system-in-head-and-neck-cancers-therapeutic-considerations
#1
Madison Grinnell, Mridula Krishnan, Apar Kishor Ganti
Immunotherapy applications for head and neck squamous cell carcinoma (HNSCC) are rapidly evolving. The progress towards immunotherapy has demonstrated improved outcomes for patients with HNSCC. Human papillomavirus (HPV)-associated HNSCC has a much better prognosis and differs from HPV-negative HNSCC in its genomic and immunologic profile, with strikingly higher immune cell activation and infiltration. Despite an increased incidence of HPV-associated HNSCC, and differences in immune signature based on HPV status, the management does not differ from non-HPV tumors...
April 10, 2020: Oncology (Williston Park, NY)
https://read.qxmd.com/read/32293694/fda-approves-nivolumab-plus-ipilimumab-for-the-treatment-of-advanced-hcc
#2
Kevin Wright
No abstract text is available yet for this article.
April 10, 2020: Oncology (Williston Park, NY)
https://read.qxmd.com/read/32293693/advancing-the-field-of-breast-cancer-care
#3
Joyce O'Shaughnessy
No abstract text is available yet for this article.
April 10, 2020: Oncology (Williston Park, NY)
https://read.qxmd.com/read/32293692/69-year-old-man-with-castration-resistant-prostate-cancer-progressing-after-docetaxel-and-androgen-receptor-targeting-agent
#4
Eduardo Gonzalez-Ochoa, Haydee Verduzco-Aguirre, E David Crawford, María T Bourlon
KEY POINTS • The prognosis for patients with mCRPC has improved over the last few years due to the introduction of novel agents. • The optimal sequence of administering these therapeutic agents remains as a moving target and is not well established. Decisions are usually made according to patients' clinical conditions and disease characteristics, and the safety profile and availability of new drugs. • Recently, cabazitaxel improved outcomes in the third-line setting after docetaxel and an ARTA. Olaparib is an additional option for second- and third-line treatment in those with alterations in BRCA1, BRCA2, and ATM...
April 10, 2020: Oncology (Williston Park, NY)
https://read.qxmd.com/read/32293691/recurrent-small-cell-carcinoma-of-the-lung-with-cutaneous-metastasis-in-breast
#5
Mehmet Sitki Copur, Adam Horn, John Allen, Carlene Springer Aprn, Thomas Zusag
Lung cancer remains the leading cause of cancer-related deaths and the second leading cause of new cancer cases in the United States. Although more commonly involving hilar nodes, the liver, adrenal glands, bones, and the brain, lung cancer can metastasize to almost any organ. Metastases, although rare in the skin may be the first sign of a lung cancer or cutaneous metastases may present as a sign of recurrent disease. The incidence of cutaneous metastases from lung cancer has been reported in approximately 1% to 12 % of cases and was associated with poor prognosis...
April 10, 2020: Oncology (Williston Park, NY)
https://read.qxmd.com/read/32293690/oncology-in-the-time-of-covid-19
#6
Howard S Hochster
No abstract text is available yet for this article.
April 10, 2020: Oncology (Williston Park, NY)
https://read.qxmd.com/read/32212136/pneumocystis-jirovecii-pneumonia-in-patients-with-metastatic-prostate-cancer-on-corticosteroids-for-malignant-spinal-cord-compression-two-case-reports-and-a-guideline-review
#7
Cassandra Duarte, Danielle Gilbert, Alison D Sheridan, Sarah D Weisdack PharmaD, Elaine T Lam
Pneumocystis jirovecii, formerly known as Pneumocystis carinii, is an atypical fungal pathogen best known for causing Pneumocystis jirovecii pneumonia (PCP). The epidemiology of PCP is changing such that patients without HIV infection now comprise the largest subset of individuals diagnosed with PCP. While those with hematologic malignancies and organ transplants are at greatest risk for non-HIV-related PCP, this review will focus on PCP in patients with solid tumors. They are at risk for PCP due to their chemotherapy regimens and use of steroids in the management of various complications of treatment, and possibly because of the immunosuppressive effect of the cancer itself...
March 19, 2020: Oncology (Williston Park, NY)
https://read.qxmd.com/read/32212135/the-lingering-questions-in-immunotherapy
#8
Kevin Wright
No abstract text is available yet for this article.
March 19, 2020: Oncology (Williston Park, NY)
https://read.qxmd.com/read/32212134/hepatocellular-carcinoma-recurrence-after-liver-transplantation
#9
Alejandro Gabutti, Sherrie Bhoori, Tommaso Cascella, Marco Bongini
Key Points • Recurrent HCC after OLT management is challenging and notoriously difficult. • High oncologic-risk patient identification and close follow-up are essential. • Recurrences diagnosed within the first 2 years after OLT can be classified as early-onset and are associated with poor prognosis. • Surgical resection should be the first curative attempt when it is technically feasible. • TACE in patients who have undergone OLT appears to be effective and safe. • Sorafenib can be used as systemic therapy in cases with multi-organ recurrence; newer therapies are emerging...
March 19, 2020: Oncology (Williston Park, NY)
https://read.qxmd.com/read/32212133/changing-the-paradigm
#10
Kenneth C Anderson
No abstract text is available yet for this article.
March 19, 2020: Oncology (Williston Park, NY)
https://read.qxmd.com/read/32212132/parp-inhibitors-as-frontline-treatment-in-patients-with-ovarian-cancer
#11
Kevin Wright
No abstract text is available yet for this article.
March 19, 2020: Oncology (Williston Park, NY)
https://read.qxmd.com/read/32212131/the-relationship-between-checkpoint-inhibitors-and-the-gut-microbiome-and-its-application-in-prostate-cancer
#12
Ashray Maniar, Amy E Moran, Julie N Graff
Indications for checkpoint inhibitors (CPIs) are growing rapidly within the field of oncology; however, they continue to have heterogeneous outcomes in different cancers. Other than mismatch repair deficiency, there are no consistent tests to determine a tumor's susceptibility. By exploring factors beyond the cancer cell, researchers have learned that the efficacy of CPIs may be governed by a myriad of variable host factors, including the tumor microenvironment (TME) and gut microbiome (GMB). The GMB serves as one of the primary organs of immune defense and has well-established local and systemic effects on the host immune system...
March 19, 2020: Oncology (Williston Park, NY)
https://read.qxmd.com/read/31914196/hypercalcemia-in-a-patient-with-small-lymphocytic-lymphoma-chronic-lymphocytic-leukemia
#13
Mehmet Sitki Copur, Whitney Wedel, Pornchai Jonglertham, Carlene Springer Aprn, Adam Horn
No abstract text is available yet for this article.
December 16, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/31914197/breast-reconstruction-in-the-setting-of-postmastectomy-radiotherapy-controversies-and-disparities
#14
Tran B Ho, William C Wood, Preeti D Subhedar Mspt
The complex decision of breast reconstruction in the setting of postmastectomy radiotherapy (PMRT) involves an understanding of the indications of PMRT and weighing the risks and benefits of various reconstruction options suitable for each patient. Classic indications for PMRT include patients with at least T3 tumors, 4 or more positive lymph nodes, and/or positive surgical margins. The benefit of PMRT in patients with T1-T2 tumors with 1 to 3 positive lymph nodes, however, remains unclear. Breast reconstruction is known to improve quality of life in breast cancer patients...
December 13, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/31914203/understanding-lung-cancer-treatment-advances
#15
(no author information available yet)
No abstract text is available yet for this article.
December 12, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/31914202/evaluating-the-role-of-targeted-therapy-in-lung-cancer
#16
Heather Wakelee
No abstract text is available yet for this article.
December 12, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/31914201/novel-combination-shows-strong-antitumor-activity-in-metastatic-renal-cell-carcinoma
#17
Kristie L Kahl
No abstract text is available yet for this article.
December 12, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/31914200/the-future-of-car-t-cell-therapy
#18
Hannah Slater
No abstract text is available yet for this article.
December 12, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/31914199/reassessing-cancer-survivorship-in-the-era-of-personalized-medicine
#19
(no author information available yet)
No abstract text is available yet for this article.
December 12, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/31914198/molecular-characterization-and-treatment-of-pancreatic-neuroendocrine-tumors
#20
Ana Maria Cristina De Jesus-Acosta
No abstract text is available yet for this article.
December 12, 2019: Oncology (Williston Park, NY)
journal
journal
29689
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"